Bio-Thera Approved to Launch Humira Biosimilar in China

23:49 EST 7 Nov 2019 | ChinaBio Today

Bio-Thera Solutions of Guangzhou was approved for a China launch of Qletli® (格乐立®), its biosimilar to autoimmune disease treatment Humira, the world's best selling drug. Qletli, the first Humira biosimilar approved in China, will be indicated for the same three conditions as the original drug: rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis. Bio-Thera develops biosimilars and novel drugs for cancer, autoimmune and cardiovascular diseases. The company will also seek approvals for Qletli in other markets. More details....

Share this with colleagues:

Original Article: Bio-Thera Approved to Launch Humira Biosimilar in China


More From BioPortfolio on "Bio-Thera Approved to Launch Humira Biosimilar in China"

Quick Search

Relevant Topics

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...